Literature DB >> 22997110

CMS to compensate hospitals for inpatient use of fidaxomicin, glucarpidase.

Cheryl A Thompson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22997110     DOI： 10.2146/news120070

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  2 in total

1.  Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.

Authors:  Jeffrey R Scott; Yinmei Zhou; Cheng Cheng; Deborah A Ward; Hope D Swanson; Alejandro R Molinelli; Clinton F Stewart; Fariba Navid; Sima Jeha; Mary V Relling; Kristine R Crews
Journal:  Pediatr Blood Cancer       Date:  2015-01-28       Impact factor: 3.167

2.  Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.

Authors:  Jason C Gallagher; Joseph P Reilly; Bhagyashri Navalkele; Gemma Downham; Kevin Haynes; Manish Trivedi
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.